Administer

Administer's Q1 missed our estimates, with Silta and EmCe driving the sales shortfall and cost savings yet to fully offset lower volumes on profitability. FY26 guidance and management commentary signal an H2-led recovery.

Administer's Q1 results came in clearly below our expectations, with net sales declining 6% and EBITDA dropping sharply by 41% y/y. The miss was driven by unexpected weakness in Silta (customer contract terminations) and EmCe (delayed project starts)...

Administer reports Q1 figures on May 13. We expect a slight topline decline alongside improved profitability on efficiency measures. The focus, however, is on FY26 guidance, progress on the Sarastia integration and market commentary.